F. Müller‐Spahn

6.9k total citations
124 papers, 5.2k citations indexed

About

F. Müller‐Spahn is a scholar working on Psychiatry and Mental health, Physiology and Cellular and Molecular Neuroscience. According to data from OpenAlex, F. Müller‐Spahn has authored 124 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Psychiatry and Mental health, 30 papers in Physiology and 19 papers in Cellular and Molecular Neuroscience. Recurrent topics in F. Müller‐Spahn's work include Schizophrenia research and treatment (34 papers), Alzheimer's disease research and treatments (28 papers) and Electroconvulsive Therapy Studies (15 papers). F. Müller‐Spahn is often cited by papers focused on Schizophrenia research and treatment (34 papers), Alzheimer's disease research and treatments (28 papers) and Electroconvulsive Therapy Studies (15 papers). F. Müller‐Spahn collaborates with scholars based in Switzerland, Germany and United States. F. Müller‐Spahn's co-authors include Egemen Savaskan, Gianfranco Olivieri, Christoph Höck, Anne Eckert, Fides Meier, C. Hock, Anna Wirz‐Justice, Ralf Jockers, Ginette Baysang and Wernér E.G. Müller and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and NeuroImage.

In The Last Decade

F. Müller‐Spahn

120 papers receiving 5.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. Müller‐Spahn Switzerland 44 1.6k 1.2k 1.1k 778 729 124 5.2k
Andrew Satlin United States 45 1.9k 1.2× 2.1k 1.7× 966 0.9× 905 1.2× 1.4k 2.0× 103 6.9k
J. Wesson Ashford United States 39 2.0k 1.3× 2.0k 1.6× 665 0.6× 566 0.7× 868 1.2× 147 5.2k
Greer M. Murphy United States 39 1.4k 0.9× 1.1k 0.9× 998 0.9× 709 0.9× 796 1.1× 90 4.9k
Giuseppe Sancesario Italy 47 1.6k 1.0× 1.1k 0.9× 1.6k 1.5× 1.8k 2.3× 1.2k 1.6× 149 6.4k
Holger Jahn Germany 37 1.1k 0.7× 794 0.6× 1.2k 1.2× 881 1.1× 444 0.6× 118 4.5k
Daniel Bandy United States 27 3.1k 2.0× 2.2k 1.8× 856 0.8× 512 0.7× 1.4k 1.9× 37 5.6k
Brenna Cholerton United States 36 2.9k 1.9× 1.4k 1.2× 1.1k 1.0× 849 1.1× 573 0.8× 95 6.7k
Peter Schönknecht Germany 36 1.5k 1.0× 1.5k 1.2× 583 0.6× 404 0.5× 1.2k 1.6× 104 4.1k
Hiroaki Hori Japan 38 613 0.4× 1.1k 0.9× 667 0.6× 573 0.7× 1.0k 1.4× 157 5.0k
Seol‐Heui Han South Korea 38 1.6k 1.0× 1.3k 1.1× 1.1k 1.1× 613 0.8× 942 1.3× 185 5.5k

Countries citing papers authored by F. Müller‐Spahn

Since Specialization
Citations

This map shows the geographic impact of F. Müller‐Spahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Müller‐Spahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Müller‐Spahn more than expected).

Fields of papers citing papers by F. Müller‐Spahn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Müller‐Spahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Müller‐Spahn. The network helps show where F. Müller‐Spahn may publish in the future.

Co-authorship network of co-authors of F. Müller‐Spahn

This figure shows the co-authorship network connecting the top 25 collaborators of F. Müller‐Spahn. A scholar is included among the top collaborators of F. Müller‐Spahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Müller‐Spahn. F. Müller‐Spahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Müller‐Spahn, F.. (2008). Individualized preventive psychiatry: syndrome and vulnerability diagnostics. European Archives of Psychiatry and Clinical Neuroscience. 258(S5). 92–97. 10 indexed citations
2.
Höck, Christoph, Alessia Maddalena, F. Müller‐Spahn, et al.. (2003). Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42in patients with Alzheimer's disease. Amyloid. 10(1). 1–6. 82 indexed citations
3.
Mager, René, et al.. (2003). Die Behandlung der Höhenangst in einer virtuellen Umgebung. Der Nervenarzt. 74(5). 428–435. 2 indexed citations
4.
Olivieri, Gianfranco, U. Otten, Friedegund Meier, et al.. (2002). Oxidative Stress Modulates Tyrosine Kinase Receptor A and p75 Receptor (Low-Affinity Nerve Growth Factor Receptor) Expression in SHSY5Y Neuroblastoma Cells. PubMed. 2002(2). 2–10. 19 indexed citations
5.
Savaskan, Egemen, F. Müller‐Spahn, Gianfranco Olivieri, et al.. (2000). Alterations in Trk A, Trk B and Trk C Receptor Immunoreactivities in Parietal Cortex and Cerebellum in Alzheimer’s Disease. European Neurology. 44(3). 172–180. 49 indexed citations
6.
Schlienger, Raymond G., et al.. (2000). Inhibition of phenprocoumon anticoagulation by carbamazepine. European Neuropsychopharmacology. 10(3). 219–221. 8 indexed citations
7.
Hofmann, M., et al.. (2000). Serum iron and ferritin in acute neuroleptic akathisia. Psychiatry Research. 93(3). 201–207. 14 indexed citations
8.
Kasper, Siegfried & F. Müller‐Spahn. (2000). Review of quetiapine and its clinical applications in schizophrenia. Expert Opinion on Pharmacotherapy. 1(4). 783–801. 85 indexed citations
9.
Müller‐Spahn, F., et al.. (1998). Elevated response of growth hormone to graded doses of apomorphine in schizophrenic patients. Journal of Psychiatric Research. 32(5). 265–271. 16 indexed citations
10.
Höck, Christoph, Klaus Heese, F. Müller‐Spahn, et al.. (1998). Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease. Neuroscience Letters. 241(2-3). 151–154. 113 indexed citations
11.
12.
März, Pia, Klaus Heese, Christoph Höck, et al.. (1997). Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients. Neuroscience Letters. 239(1). 29–32. 58 indexed citations
13.
Stefanis, C., Hanns Hippius, & F. Müller‐Spahn. (1996). Neuropsychiatry in old age : an update. 2 indexed citations
14.
Bondy, Brigitta, et al.. (1996). The PHA-induced calcium signal in lymphocytes is altered after blockade of K+-channels in Alzheimer's disease. Journal of Psychiatric Research. 30(3). 217–227. 16 indexed citations
15.
Bondy, Brigitta, et al.. (1994). Cytosolic free [Ca2+] in mononuclear blood cells from demented patients and healthy controls. European Archives of Psychiatry and Clinical Neuroscience. 243(5). 224–228. 31 indexed citations
16.
Müller‐Spahn, F., et al.. (1994). Clinical Presentation of Depression in the Elderly. Gerontology. 40(1). 10–14. 21 indexed citations
17.
Müller‐Spahn, F., et al.. (1991). Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten. Fortschritte der Neurologie · Psychiatrie. 59(S 1). 18–22. 20 indexed citations
18.
Steiger, Axel, U. von Bardeleben, Peter Falkai, et al.. (1990). Course of biological markers during psychiatric disorders. Pharmacopsychiatry. 23. 227–228. 1 indexed citations
19.
Bandelow, Borwin, Péter Müller, Wolfgang Gäebel, et al.. (1990). Depressive syndromes in schizophrenic patients after discharge from hospital. European Archives of Psychiatry and Clinical Neuroscience. 240(2). 113–120. 19 indexed citations
20.
Louzã, Mário R., F. Müller‐Spahn, E. Rüther, & J Scherer. (1988). Haloperidol Plasma Level after a Test Dose as Predictor for the Clinical Response to Treatment in Acute Schizophrenic Patients. Pharmacopsychiatry. 21(5). 226–231. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew Satlin Breakdown of academic impact, for papers by J. Wesson Ashford Breakdown of academic impact, for papers by Greer M. Murphy Breakdown of academic impact, for papers by Giuseppe Sancesario Breakdown of academic impact, for papers by Holger Jahn Breakdown of academic impact, for papers by Daniel Bandy Breakdown of academic impact, for papers by Brenna Cholerton Breakdown of academic impact, for papers by Peter Schönknecht Breakdown of academic impact, for papers by Hiroaki Hori Breakdown of academic impact, for papers by Seol‐Heui Han
Rankless by CCL
2026